No annual revenue total was found in Latigo Biotherapeutics, Inc.'s SEC filings.
Latigo Biotherapeutics, Inc. (LTGO) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $55.0 million in cash and investments and $1.0 million in total debt.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
—
Net cash
$54.00M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LTGO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Thousand Oaks, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2056611
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Sep 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 3, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Aug 10, 2026 | Aug 10, 2026 |
All 41 Latigo Biotherapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.